HOME ȸ»ç¼Ò°³ ½ÃÀÛÆäÀÌÁö·Î Áñ°Üã±âÃß°¡ ±âÀÚȸ¿ø½Åû
[¸ð¹ÙÀϸðµå] ·Î±×ÀΠȸ¿ø°¡ÀÔ
2024³â04¿ù29ÀÏmon
±â»çÃÖÁ¾ÆíÁýÀÏ: 2024-04-29 14:16:54
´º½ºÈ¨ > µ¿Á¤
2014³â07¿ù25ÀÏ 17½Ã34ºÐ
±ÛÀÚÅ©±â ±â»ç³»¿ë À̸ÞÀϺ¸³»±â ´º½ºÇÁ¸°Æ®Çϱ⠴º½º½ºÅ©·¦Çϱâ
Çã¹Ì³ª¡¤À±¿©¹Î¡¤¹®Èñ¿ø ±³¼ö, ¡®±Þ¼º ½Å¼Õ»ó Ç¥ÁöÀÚ NGAL¡¯ Ã¥ ÁýÇÊ
¼¼°è À¯¸í ÀÇÇÐÀÚµé°ú °øÀú

°Ç±¹´ëº´¿ø Áø´Ü°Ë»çÀÇÇаú Çã¹Ì³ª·À±¿©¹Î·¹®Èñ¿ø ±³¼ö°¡ ¹Ì±¹ ´º¿åÀÇ ÀÇÇÐ ±³°ú¼­ Àü¹® ÃâÆÇ»ç ³ë¹Ù(NOVA publishers)¿¡¼­ Ãâ°£ÇÏ´Â ‘NGAL ±âÃÊ ¿¬±¸¿¡¼­ ÀÓ»ó È°¿ë±îÁö(neutrophil gelatinase-associated lipocalin: from laboratory to clinical  utility’ÀÇ ÁýÇÊÁøÀ¸·Î Âü¿©Çß´Ù.(»çÁø ¿ÞÂʺÎÅÍ ¹®Èñ¿ø·Çã¹Ì³ª·À±¿©¹Î ±³¼ö)

ÀÌ Ã¥Àº Áø´Ü°Ë»çÀÇÇÐ »Ó ¾Æ´Ï¶ó ÀÀ±ÞÀÇÇÐ, ½ÉÀåÇÐ, ½ÅÀåÇÐ, ÁßȯÀÚ ÀÇÇÐ ºÐ¾ßÀÇ ¼¼°è À¯¸í ¿¬±¸ÀÚµé°ú °øÀú·Î ¸¸µé¾îÁ³´Ù.

ÀÌ Ã¥Àº ÃÖ±Ù ±Þ¼º ½ÅÀå ¼Õ»ó Ç¥ÁöÀÚ·Î ÁÖ¸ñ¹Þ´Â NGALÀÇ ±âÃÊ ¿¬±¸ºÎÅÍ ÀÓ»ó È°¿ë±îÁö Æø³Ð°Ô ´Ù·ð´Ù.

ÀÀ±ÞÀÇÇÐ ºÐ¾ß¿£ ¹Ì±¹ º£ÀÏ·¯ ÀÇ°ú´ëÇÐÀÇ W. Frank Peackco ±³¼ö, ½ÅÀåÇÐÀº µ¶ÀÏ ¸¶±×µ¥ºÎ¸£Å© ´ëÇÐÀÇ Michael Haase ±³¼ö µîÀÌ ÇÔ²² Çß´Ù.

Çã¹Ì³ª ±³¼ö´Â ÀÌ Ã¥¿¡¼­ 15ÀåÀÎ ÆÐÇ÷Áõ ȯÀÚ¿¡¼­ÀÇ NGAL(NGAL in septic Patients)¿Í 20ÀåÀÎ NGALÀ» Æ÷ÇÔÇÑ ´Ù¸¥ ½ÅÀå ±â´É Ç¥ÁöÀÚÀÇ Á¢±Ù¹ý(Muti-Markers Approach Including NGAL and other Biomarkers)À» ¸Ã¾Æ ÁýÇÊÇß´Ù.

¶Ç ¹®Èñ¿ø ±³¼ö¿Í ÇÔ²² 11Àå NGAL vs. CreatinineÀ» ÅëÇØ ¶Ç ´Ù¸¥ ½Å±â´É Ç¥ÁöÀÚ Å©·¹¾ÆƼ´Ñ°ú NGALÀ» ºñ±³ ¼³¸íÇß´Ù.
À±¿©¹Î ±³¼ö´Â Á¦10Àå Reference Ranges and Cut-Off Values for the NGAL AssayÀ» ½è´Ù.

Çã ±³¼ö´Â ÀÌÅ»¸®¾Æ ¶ó »çÇÇ¿£ÀÚ ´ëÇÐÀÇ Salvatore Di Somma ±³¼ö¿Í °øµ¿ ÆíÁýÀÚ·Î Âü¿©Çß´Ù.
Salvatore Di Somma ±³¼ö´Â ¼¼°èÀûÀÎ ½ÉÀår°ú ÀÀ±ÞÀÇÇÐ Àü¹®ÀÇ·Î ±Þ¼º Áúȯ Àü¹®°¡µéÀÇ ¿¬±¸³×Æ®¿öÅ©ÀÎ GREAT NETWORKÀÇ È¸ÀåÀ» ¸Ã°í ÀÖ´Ù.

Çã ±³¼ö´Â NGAL ¿¬±¸¿Í °ü·ÃÇØ ´Ù¼öÀÇ ³í¹®À» ¹ßÇ¥ÇÑ Áø´ÜÀÇÇÐºÐ¾ß Àü¹®°¡´Ù.

´ëÇ¥ÀûÀ¸·Î Áö³­ 4¿ù¿£ ÆÐÇ÷ÁõÀÌ ÀǽɵǴ ȯÀÚÀÇ »óŸ¦ Áø´Ü, ¿¹Èĸ¦ ¿¹ÃøÇϱâ À§ÇÑ Ç¥ÁöÀÚ·Î PCT(procalcitonin)¿Í BNP(B-type natriuretic peptide), NGALÀ» ºÐ¼®ÇÑ ³»¿ëÀ¸·Î Àú³Î BMC Infectious Diseases¿¡ ³í¹®À» °ÔÀçÇß´Ù.

Áö³­ÇØ¿£ Àú³Î Clinical Biochemistry¿¡ ÆÐÇ÷Áõ ÀÇ½É È¯ÀÚÀÇ ±Ø½ÉÇÑ ½ÅÀå ¼Õ»óÀ» È®ÀÎÇϱâ À§ÇÑ Ç¥ÁöÀڷμ­ÀÇ NGALÀ» ÁÖÁ¦·Î ³í¹®À» ¹ßÇ¥Çß´Ù.

*Diagnostic and prognostic utilities of multimarkers approach using procalcitonin, B-type natriuretic peptide, and neutrophil gelatinase-associated lipocalin in critically ill patients with suspected sepsis(BMC Infectious Diseases,2014)

*Plasma neutrophil gelatinase-associated lipocalin as a biomaker for acute kidney injury in critically ill patients with suspected sepsis(Clinical Biochemistry,2013)

 

 

 

 

 

°ü·Ã±â»ç°¡ ¾ø½À´Ï´Ù
´º½º½ºÅ©·¦Çϱâ
Á¶ÇöÁø (bktimes@naver.com) ±âÀÚ 
À̱âÀÚÀÇ ´Ù¸¥´º½ºº¸±â
µ¿Á¤¼½¼Ç ¸ñ·ÏÀ¸·Î
±è¿Á¹è ±³¼ö, ±¹¹«ÃѸ®»ó ...
¼­¿ï´ëº´¿ø ½Å°æ°ú ¿¬±¸ÆÀ ...
´ë°¡´ëº´¿ø ÃÖÀ翵 ±³Á÷¿ø,...
±è¿µÈ¿ ±³¼ö, ¡®¸¶¸£ÄûÁî ...
ÍÔÓÞ È«¼øÁØ ±³¼ö, ¡®ÁßÀç...
´ÙÀ½±â»ç : ÇѿùÙÀÌ¿ÀÆĸ¶ ÀÌÇüö ºÎÀå, ¡®Çѱ¹Àç´É³ª´®´ë»ó¡¯ ¼ö»ó (2014-07-28 09:31:10)
ÀÌÀü±â»ç : ¹®Á¾È£ ±³¼ö Ú¸ ±¹Á¦½ÉÆ÷Áö¾ö ¡®ÄÚ½º µð·ºÅÍ¡¯¿¡ À§ÃË (2014-07-25 10:07:44)
º´¿ø°è, "°è...
º´¿ø°è, "°è¹¦³â...
Á¦¾à¡¤°Ç½Ä 12°³...
°Çº¸°ø´Ü, ¼Ò¼Ó±â°ü '¼­¿ï¿ä¾ç...
¼ºÀåÇÏ°íÇ ´ç½Å, "Áö±Ý ´ë¿õ,...
º¸·ÉÁ¦¾à, ¿Ã »ó¹Ý±â '¿µ¾÷Á÷ ...
°Çº¸°ø´Ü, ¿ÃÇØ '°³¹æÇü Á÷°ú ...
°Çº¸°ø´Ü, '¿Ã Á¦3Â÷ °³¹æÇü ...
³í¹®) Wearable and stretchable conductive polymer....
ȸ»ç¼Ò°³ °³ÀÎÁ¤º¸º¸È£Á¤Ã¥ ÀÌ¿ë¾à°ü À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ ¾Ë¸³´Ï´Ù º¸µµÀÚ·á ±â»çÁ¦º¸ Á¤±â±¸µ¶